Filing Flows › ResMed (RMD) › Q4 FY26 › vs Q4 FY25
ResMed (RMD) Q4 FY26 vs Q4 FY25 (year over year)
ResMed's revenue rose $116M (+9%) from $1.3B in Q4 FY25 to $1.5B in Q4 FY26. Gross margin 58.8% against 60.8% (-2.0 pts).
ResMed, Q4 FY26: revenue $1.5B (+9% year over year), operating margin 30.7%, net earnings $383M, operating cash flow $455M. The chart draws each line against Q4 FY25, the increases inside each band.
Margins
| Q4 FY26 | Q4 FY25 | Change | |
|---|---|---|---|
| Gross margin | 58.8% | 60.8% | -2.0 pts |
| Operating margin | 30.7% | 33.7% | -3.1 pts |
| Net margin | 26.2% | 28.2% | -2.0 pts |
| Free cash flow margin | 27.6% | 37.7% | -10.1 pts |
Every line
| Line | Q4 FY26 | Q4 FY25 | Change | % |
|---|---|---|---|---|
| Revenue | $1.5B | $1.3B | $116M | +9% |
| Gross profit | $861M | $820M | $41.2M | +5% |
| Cost of revenue | $602M | $528M | $74.5M | +14% |
| Other income, net | $25.5M | $3.5M | $21.9M | +625% |
| Operating profit | $449M | $455M | −$5.8M | -1% |
| Operating expenses | $413M | $366M | $47.0M | +13% |
| Pre-tax earnings | $474M | $458M | $16.1M | +4% |
| Research & development | $106M | $86.4M | $19.3M | +22% |
| SG&A | $296M | $267M | $29.1M | +11% |
| Other operating costs | $10.5M | $11.9M | −$1.4M | -12% |
| Net earnings | $383M | $380M | $3.7M | +1% |
| Income tax | $90.7M | $78.3M | $12.4M | +16% |
| Depreciation & amortization | $44.8M | $63.6M | −$18.9M | -30% |
| Share-based compensation | $27.5M | $24.8M | $2.7M | +11% |
| Working capital & other | $1.0M | −$70.7M | $71.7M | — |
| Operating cash flow | $455M | $539M | −$84.1M | -16% |
| Free cash flow (OCF − capex) | $404M | $508M | −$105M | -21% |
| Capital expenditures | $51.1M | $30.6M | $20.5M | +67% |
Questions
How much did ResMed's revenue grow year over year in Q4 FY26?
ResMed's revenue rose $116M (+9%) from $1.3B in Q4 FY25 to $1.5B in Q4 FY26. Gross margin 58.8% against 60.8% (-2.0 pts).